Gilead opts for $3,120 US in­sur­er price for Covid-19 drug remde­sivir — but some say it should be free

Last month
Pharma

Covid-19 roundup: Temasek leads a $250M raise for BioN­Tech as first Covid-19 mR­NA vac­cine da­ta looms; Chi­na's mil­i­tary OKs first use of coro­n­avirus vac­cine

Last month
Coronavirus

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Last month
R&D
Cell/Gene Tx

No­var­tis yanks ap­pli­ca­tion from the EMA af­ter reg­u­la­tors say re­searchers nev­er proved ef­fi­ca­cy of their $3.4B dry eye drug

Last month
Regulatory

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

Last month
Pharma

Af­ter 2 de­lays, Zo­genix nabs FDA ap­proval for epilep­sy drug, sets price at 3X its GW Phar­ma com­peti­tor

Last month
Pharma
Regulatory

Ab­b­Vie’s first post-merg­er Al­ler­gan drug pitch strikes out with the FDA as reg­u­la­tors turn thumbs down on Lu­cen­tis chal­lenger

Last month
Regulatory

Re­lay and iTeos join IPO del­uge while Ak­ou­os and Fu­sion de­cide they can earn more

Last month
IPOs

Over a decade ago, a dis­as­trous tri­al killed re­search on a po­ten­tial im­munother­a­py. Can a Re­gen­eron bis­pe­cif­ic re­vive it?

Last month
R&D

Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

Last month
People
R&D

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

Last month
Deals
Cell/Gene Tx

Ac­celeron promised they had great da­ta on so­tater­cept in late Jan­u­ary. But was it good enough to jus­ti­fy a dou­bling of the stock price?

Last month
R&D

Is it re­al­ly over? La Jol­la signs ac­qui­si­tion with Tetraphase af­ter out­bid­ding Acel­Rx, Melin­ta

Last month
Deals

Burned by Alzheimer’s fail­ures, a cau­tious Mer­ck turns to a start­up biotech for some pre­clin­i­cal neu­ro pro­grams

Last month
Deals
R&D

UK Supreme Court strikes down Re­gen­eron patents, open­ing door for Kymab

Last month
Pharma

With its cam­pus ex­pand­ing as gene ther­a­py booms, Alde­vron brings in a top ex­ec from a medtech gi­ant to steer the course

Last month
People
Cell/Gene Tx

My­ovant read­ies NDA #3 as re­l­u­golix sails to its 5th pos­i­tive PhI­II — this time in en­dometrio­sis

Last month
R&D
Regulatory

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

Last month
People
Deals

Sanofi wants to earn the rep for be­ing the hare in drug R&D. But that darn tor­toise keeps stick­ing its head out

Last month
R&D

Sanofi bets $425M cash on a trans­for­ma­tion-style next-gen vac­cine deal — as the Big Phar­ma team makes a point

Last month
Deals

Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

Last month
R&D

Mer­ck ad­vances along a broad PhI­II front, aimed at carv­ing up Pfiz­er’s top-sell­ing vac­cine fran­chise. Could an am­bush lay in wait?

Last month
R&D

Cell and gene ther­a­py 2.0 dom­i­nates lat­est round of biotech IPOs in scram­ble for a $300M-plus Nas­daq wind­fall

Last month
IPOs
Cell/Gene Tx

Covid-19 roundup: In fifth open let­ter, Daniel O’Day touts in­halant remde­sivir, promis­es 2M dos­es by year's end; Mer­ck’s an­tivi­ral moves in­to PhII

Last month
Coronavirus
First page Previous page 2345678 Next page Last page